Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis

J. M. Mondesir; J. M. Bidart; A. Goodman; G. F. Alberici; P. Caille; F. Troalen; J. Rouesse; C. Bohuon; R. J. Gralla; A. I. Einzig

doi:10.1200/JCO.1985.3.5.735

Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis

J. M. Mondesir, J. M. Bidart, A. Goodman, G. F. Alberici, P. Caille, F. Troalen, J. Rouesse, C. Bohuon, R. J. Gralla, A. I. Einzig

Medicine

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Drug-dependent antibodies were investigated in patients treated with elleptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers ≥ 32 were at risk for hemolysis. The possible mechanisms are discussed.

Original language	English (US)
Pages (from-to)	735-740
Number of pages	6
Journal	Journal of Clinical Oncology
Volume	3
Issue number	5
DOIs	https://doi.org/10.1200/JCO.1985.3.5.735
State	Published - Jan 1 1985

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.1985.3.5.735

Cite this

Mondesir, J. M., Bidart, J. M., Goodman, A., Alberici, G. F., Caille, P., Troalen, F., Rouesse, J., Bohuon, C., Gralla, R. J., & Einzig, A. I. (1985). Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis. Journal of Clinical Oncology, 3(5), 735-740. https://doi.org/10.1200/JCO.1985.3.5.735

Mondesir, JM, Bidart, JM, Goodman, A, Alberici, GF, Caille, P, Troalen, F, Rouesse, J, Bohuon, C, Gralla, RJ & Einzig, AI 1985, 'Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis', Journal of Clinical Oncology, vol. 3, no. 5, pp. 735-740. https://doi.org/10.1200/JCO.1985.3.5.735

@article{3ec9e31523f24afaa94d0dfe1e98d140,

title = "Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis",

abstract = "Drug-dependent antibodies were investigated in patients treated with elleptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers ≥ 32 were at risk for hemolysis. The possible mechanisms are discussed.",

author = "Mondesir, {J. M.} and Bidart, {J. M.} and A. Goodman and Alberici, {G. F.} and P. Caille and F. Troalen and J. Rouesse and C. Bohuon and Gralla, {R. J.} and Einzig, {A. I.}",

year = "1985",

month = jan,

day = "1",

doi = "10.1200/JCO.1985.3.5.735",

language = "English (US)",

volume = "3",

pages = "735--740",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "5",

}

TY - JOUR

T1 - Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment

T2 - Schedule dependency and relationship to hemolysis

AU - Mondesir, J. M.

AU - Bidart, J. M.

AU - Goodman, A.

AU - Alberici, G. F.

AU - Caille, P.

AU - Troalen, F.

AU - Rouesse, J.

AU - Bohuon, C.

AU - Gralla, R. J.

AU - Einzig, A. I.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Drug-dependent antibodies were investigated in patients treated with elleptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers ≥ 32 were at risk for hemolysis. The possible mechanisms are discussed.

AB - Drug-dependent antibodies were investigated in patients treated with elleptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers ≥ 32 were at risk for hemolysis. The possible mechanisms are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0021958114&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021958114&partnerID=8YFLogxK

U2 - 10.1200/JCO.1985.3.5.735

DO - 10.1200/JCO.1985.3.5.735

M3 - Article

C2 - 3998787

AN - SCOPUS:0021958114

SN - 0732-183X

VL - 3

SP - 735

EP - 740

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 5

ER -

Drug-induced antibodies during 2-N-methyl-9-hydroxyellepticinium acetate (NSC-264137) treatment: Schedule dependency and relationship to hemolysis

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this